D. Hong
Epidemiology · New England Journal of Medicine · 2011–2020
A researcher in the Science corpus: 8 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Epidemiology — 57 citations into it
- Pharmacology — 5 citations into it
Whom D. Hong trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from D. Hong's perspective
Ordered by how strongly the researchers D. Hong trusts endorse each paper. Same corpus, a different order for every researcher.
- Role for Rab7 in maturation of late autophagic vacuoles (Journal of Cell Science)
- LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing (EMBO Journal)
- Growth factor regulation of autophagy and cell survival in the absence of apoptosis. (Cell)
- Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin (Nature)
- Autophagy: process and function. (Genes & Development)
- Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes (Autophagy)
- Autophagy in the pathogenesis of disease. (Cell)
- Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor (Proceedings of the National Academy of Sciences of the United States of America)
- Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. (Journal of Clinical Investigation)
- Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. (Journal of Clinical Investigation)
Their papers
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children (2018) — 2,224 citations
- Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. (2015) — 375 citations
- Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors (2016) — 788 citations
- Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours (2020) — 801 citations
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials (2020) — 809 citations
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors (2020) — 833 citations
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity (2019) — 1,899 citations
- Autophagy as a target for anticancer therapy (2011) — 797 citations